<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1142">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146284</url>
  </required_header>
  <id_info>
    <org_study_id>PXL770-011</org_study_id>
    <nct_id>NCT05146284</nct_id>
  </id_info>
  <brief_title>Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)</brief_title>
  <official_title>A Randomized Open-label Phase 2a Study to Assess PXL770 After 12 Weeks of Treatment in Male Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic&#xD;
      parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy&#xD;
      (AMN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic&#xD;
      parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy&#xD;
      (AMN).&#xD;
&#xD;
      There are 3 study periods.&#xD;
&#xD;
        -  Screening Visit: within a maximum of 4 weeks prior to the open-label Treatment Period&#xD;
&#xD;
        -  Open-label Treatment Period: 12 weeks&#xD;
&#xD;
        -  Follow-up Period: 2 weeks after the last intake of the treatment&#xD;
&#xD;
      During the treatment period, VLCFA will be assessed every 4 weeks, to evaluate the kinetics&#xD;
      of the effect. NfL will be assessed after 8 and 12 weeks of treatment, and other exploratory&#xD;
      biomarkers after 12 weeks of treatment. A follow up period will allow monitoring the&#xD;
      subjects' safety as well as the duration of the effect on the 2 main biomarkers (VLCFA and&#xD;
      NfL) at 2 and 4 weeks after the drug withdrawal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters</measure>
    <time_frame>4 week</time_frame>
    <description>Peak plasma concentration (Cmax) for 500mg QD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pk parameters</measure>
    <time_frame>4 week</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)0-24 for 500mg QD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>4 week</time_frame>
    <description>Cmax for 250mg BID</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>4 week</time_frame>
    <description>AUC0-8 for 250mg BID</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Adrenomyeloneuropathy</condition>
  <arm_group>
    <arm_group_label>PXL770 500 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PXL770 250 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXL770</intervention_name>
    <description>Tablet</description>
    <arm_group_label>PXL770 250 mg BID</arm_group_label>
    <arm_group_label>PXL770 500 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects with either a confirmed diagnosis of AMN by genetic testing (mutation in&#xD;
             the ATP binding cassette subfamily D (ABCD1 gene)) or a family history of X-linked&#xD;
             adrenoleukodystrophy (ALD) together with an elevation in VLCFA obtained from overnight&#xD;
             fasting plasma sample at Screening Visit (V1).&#xD;
&#xD;
          -  Age: ≥ 18 to ≤ 65 years at informed consent signature.&#xD;
&#xD;
          -  Normal brain magnetic resonance imaging (MRI) or brain MRI showing non-specific&#xD;
             abnormalities that can be observed in AMN subjects without signs of cerebral form of&#xD;
             ALD (C-ALD). MRI must be performed within 6 months prior to V2. If there is no&#xD;
             available brain MRI within this period, a brain MRI must be performed before V2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any progressive neurological disease other than AMN.&#xD;
&#xD;
          -  Arrested or progressing C-ALD as defined by cerebral lesions (except for non-specific&#xD;
             abnormalities that can be observed in AMN subjects).&#xD;
&#xD;
          -  Prior receipt of an allogeneic hematopoietic stem cell transplant or gene therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

